儿童及青少年肉瘤评估中非罗莫司醇与钆螯合物增强MRI的比较
回顾性比较22例新诊断骨或软组织肉瘤儿童及青少年中非罗莫司醇增强MRI与钆增强MRI的评估价值,两种方案间隔不超过4周。结果显示肿瘤体积评估无显著差异,非罗莫司醇MRI在肿瘤与骨髓、肝脏和血管的对比度以及神经血管束受累和瘤栓评估信心上更优,作者认为非罗莫司醇MRI可作为钆增强MRI的替代方案用于肿瘤分期。
要点
- 非罗莫司醇增强MRI与钆增强MRI在评估儿童及青少年骨和软组织肉瘤肿瘤体积方面无显著差异。
- 非罗莫司醇MRI在T2-FSE序列上肿瘤与骨髓对比度显著更高,在T1-LAVA序列上肿瘤与肝脏、血管对比度显著更高。
- 非罗莫司醇MRI对神经血管束受累和瘤栓的评估信心显著更高,可能有助于肿瘤分期。
关键影像表现/征象
- T1-LAVA、T1-SE和T2-FSE序列上肿瘤体积在非罗莫司醇与钆增强MRI间无显著差异(p=0.721、p=0.290、p=0.609)。
- 与钆增强MRI相比,非罗莫司醇MRI在T1-LAVA序列上肿瘤信噪比显著更低(p<0.001),在T1-SE和T2-FSE序列上肿瘤信噪比无显著差异(p=0.104、p=0.305)。
- 非罗莫司醇MRI在T2-FSE序列上肿瘤与骨髓对比噪声比显著更高(p<0.001),在T1-LAVA序列上肿瘤与肝脏和血管对比噪声比显著更高(p=0.021、p=0.003)。
- 钆增强MRI上瘤周水肿和骨髓水肿的强化程度显著高于非罗莫司醇MRI(p<0.001、p=0.002)。
- 非罗莫司醇MRI评估瘤栓和神经血管束受累的置信度显著更高(均p<0.001)。
诊断标准与关键数值
- 四名读者按15项诊断参数使用Likert量表评分,结果合并后比较非罗莫司醇与钆增强MRI。
- 肿瘤信噪比在T1-LAVA序列上非罗莫司醇MRI显著低于钆增强MRI(p<0.001),在T1-SE和T2-FSE序列上无显著差异(p=0.104、p=0.305)。
- 肿瘤与骨髓对比噪声比在T2-FSE序列上非罗莫司醇MRI显著高于钆增强MRI(p<0.001);肿瘤与肝脏和血管对比噪声比在T1-LAVA序列上非罗莫司醇MRI显著更高(p=0.021、p=0.003)。
临床应用与阅片要点
- 非罗莫司醇MRI在T2-FSE序列上提供更高的肿瘤与骨髓对比噪声比,可能有助于 delineation 骨和软组织肉瘤与骨髓的边界。
- 非罗莫司醇MRI在T1-LAVA序列上提供更高的肿瘤与肝脏和血管对比噪声比,可能有助于评估肿瘤与血管的关系。
- 非罗莫司醇MRI评估神经血管束受累和瘤栓的置信度显著更高,阅片时可关注这些结构。
- 钆增强MRI上瘤周水肿和骨髓水肿强化更明显,阅片时需注意两种方案在水肿显示上的差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We compared the value of ferumoxytol (FMX)- and gadolinium (Gd)-enhanced MRI for assessment of sarcomas in paediatric/adolescent patients and hypothesised that tumour size and morphological features can be equally well assessed with both protocols.
METHODS: We conducted a retrospective study of paediatric/adolescent patients with newly diagnosed bone or soft tissue sarcomas and both pre-treatment FMX- and Gd-MRI scans, which were maximal 4 weeks apart. Both protocols included T1- and T2-weighted sequences. One reader assessed tumour volumes, signal-to-noise ratios (SNR) of the primary tumour and adjacent tissues and contrast-to-noise ratios (CNR) of FMX- and Gd-MRI scans. Additionally, four readers scored FMX- and Gd-MRI scans according to 15 diagnostic parameters, using a Likert scale. The results were pooled across readers and compared between FMX- and Gd-MRI scans. Statistical methods included multivariate analyses with different models.
RESULTS: Twenty-two patients met inclusion criteria (16 males, 6 females; mean age 15.3 ± 5.0). Tumour volume was not significantly different on T1-LAVA (p = 0.721), T1-SE (p = 0.290) and T2-FSE (p = 0.609) sequences. Compared to Gd-MRI, FMX-MRI demonstrated significantly lower tumour SNR on T1-LAVA (p < 0.001), equal tumour SNR on T1-SE (p = 0.104) and T2-FSE (p = 0.305), significantly higher tumour-to-marrow CNR (p < 0.001) on T2-FSE as well as significantly higher tumour-to-liver (p = 0.021) and tumour-to-vessel (p = 0.003) CNR on T1-LAVA images. Peritumoural and marrow oedema enhanced significantly more on Gd-MRI compared to FMX-MRI (p < 0.001/p = 0.002, respectively). Tumour thrombi and neurovascular bundle involvement were assessed with a significantly higher confidence on FMX-MRI (both p < 0.001).
CONCLUSIONS: FMX-MRI provides equal assessment of the extent of bone and soft tissue sarcomas compared to Gd-MRI with improved tumour delineation and improved evaluation of neurovascular involvement and tumour thrombi. Therefore, FMX-MRI is a possible alternative to Gd-MRI for tumour staging in paediatric/adolescent sarcoma patients.
KEY POINTS: • Ferumoxytol can be used as an alterative to gadolinium chelates for MRI staging ofpaediatric sarcomas. • Ferumoxytol-enhanced MRI provides equal assessment of tumour size and other diagnostic parameters compared to gadolinium chelate-enhanced MRI. • Ferumoxytol-enhanced MRI provides improved delineation of sarcomas from bone marrow, liver and vessels compared to gadolinium chelate-enhanced MRI.
引用
- Siedek F, Muehe AM, Theruvath AJ, et al. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. Eur Radiol. 2019. PMID: 31844962. doi:10.1007/s00330-019-06569-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。